Catalyst Pharmaceuticals chair reports stock gifts to family trusts

Q: What insider transaction did Catalyst Pharmaceuticals (CPRX) report in this Form 4?

The Form 4 reports that chairman and director Patrick J. McEnany made bona-fide gifts of common stock of Catalyst Pharmaceuticals, recorded as transactions with code "G" at a price of $0 per share.

Q: When did the reported Catalyst Pharmaceuticals (CPRX) stock gifts occur?

The earliest transaction date reported is 12/01/2025, which is when the gifts of Catalyst Pharmaceuticals common stock took place.

Q: Does the reporting person control investment decisions for the trusts holding CPRX shares?

No. It is specifically noted that the reporting person is not a trustee of any of the trusts and has no direct or indirect influence over their investment decisions.

Q: What is the reporting person’s relationship to Catalyst Pharmaceuticals (CPRX)?

The reporting person is identified as a Director and Chairman of the Board of Directors of Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (CPRX) chairman of the board and director Patrick J. McEnany reported stock gifts to family trusts.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Catalyst Pharmaceuticals, Inc. (CPRX) chairman of the board and director Patrick J. McEnany reported stock gifts to family trusts. On 12/01/2025, he made bona-fide gifts of common stock, par value $0.001 per share, recorded at a price of $0 per share, classified under transaction code "G" for gifts. After the reported transactions, he directly beneficially owned 4,148,477 shares of Catalyst Pharmaceuticals common stock. The explanation notes that the gifts were to irrevocable trusts for family members who do not share his household, and he is not a trustee and has no direct or indirect influence over the trusts' investment decisions.

Insider Trade Summary

135,000 shares gifted

Gift 3 txns

Insider MCENANY PATRICK J

Role Director

Type	Security	Shares	Price	Value
Gift	Common stock, par value $0.001 per share	45,000	$0.00	$0.00
Gift	Common stock, par value $0.001 per share	45,000	$0.00	$0.00
Gift	Common stock, par value $0.001 per share	45,000	$0.00	$0.00

Holdings After Transaction: Common stock, par value $0.001 per share — 4,148,477 shares (Direct)

Footnotes (1)

F1. These transactions involved bona-fide gifts to irrevocable trusts for the benefit of family members of the Reporting Person. The beneficiaries do not share a household with the Reporting Person. The Reporting Person is not a trustee of any of the trusts, and the Reporting Person has no influence, whether direct or indirect, regarding investment decisions by the trusts.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Catalyst Pharmaceuticals (CPRX) report in this Form 4?

The Form 4 reports that chairman and director Patrick J. McEnany made bona-fide gifts of common stock of Catalyst Pharmaceuticals, recorded as transactions with code "G" at a price of $0 per share.

When did the reported Catalyst Pharmaceuticals (CPRX) stock gifts occur?

The earliest transaction date reported is 12/01/2025, which is when the gifts of Catalyst Pharmaceuticals common stock took place.

How many Catalyst Pharmaceuticals (CPRX) shares does the reporting person own after the gifts?

Following the reported gift transactions, Patrick J. McEnany directly beneficially owned 4,148,477 shares of Catalyst Pharmaceuticals common stock.

Who received the gifted Catalyst Pharmaceuticals (CPRX) shares?

The explanation states that the transactions were bona-fide gifts to irrevocable trusts for the benefit of family members of the reporting person. The beneficiaries do not share a household with him.

Does the reporting person control investment decisions for the trusts holding CPRX shares?

No. It is specifically noted that the reporting person is not a trustee of any of the trusts and has no direct or indirect influence over their investment decisions.

What is the reporting person’s relationship to Catalyst Pharmaceuticals (CPRX)?

The reporting person is identified as a Director and Chairman of the Board of Directors of Catalyst Pharmaceuticals, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 12/03/2025 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCENANY PATRICK J

(Last)

(First)

(Middle)

355 ALHAMBRA CIRCLE, SUITE 801

(Street)

CORAL GABLES

33134

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Chairman of Board of Directors

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock, par value $0.001 per share	12/01/2025		G		45,000⁽¹⁾	D	$0	4,328,477	D
Common stock, par value $0.001 per share	12/01/2025		G		45,000⁽¹⁾	D	$0	4,193,477	D
Common stock, par value $0.001 per share	12/01/2025		G		45,000⁽¹⁾	D	$0	4,148,477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions involved bona-fide gifts to irrevocable trusts for the benefit of family members of the Reporting Person. The beneficiaries do not share a household with the Reporting Person. The Reporting Person is not a trustee of any of the trusts, and the Reporting Person has no influence, whether direct or indirect, regarding investment decisions by the trusts.

	/s/ Patrick J. McEnany	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR